Quick Facts

• Relief Target: Symptoms related to dry eye, including burning and itching.
• Primary Action: Supports the maintenance of moisture and lubrication on the eye's surface.
• Use Context: Indicated for occasional or chronic eye dryness due to environmental factors, aging, or certain health conditions.

Artificial tear solutions are utilized to address discomfort associated with dry eye conditions. Their primary benefit is to supplement the natural tear film, promoting the maintenance of moisture on the ocular surface. This lubrication can help reduce friction on the cornea, which in turn supports the alleviation of symptoms such as a gritty or scratchy sensation, burning, and irritation.

The use of these drops is associated with providing temporary relief for dryness caused by environmental factors like wind, sun exposure, or prolonged screen time. They may also support eye comfort in individuals experiencing chronic dry eye due to aging or certain underlying health issues. Artificial tears are a foundational option in the management of dry eye syndrome. Their mechanism helps maintain a healthy visual environment by ensuring the surface of the eye remains adequately lubricated.

Regulatory References

1. NIH MedlinePlus guidance on dry eye

Eligibility for Artificial Tears: Official Regulatory Information

Artificial tears are generally recognized as safe for use in the general adult population. However, use is contraindicated for individuals with a known hypersensitivity or allergy to the product or any of its components.

Category	Eligibility Status (Regulatory Basis)
Contraindicated	Individuals with known allergy to the product or its components.
Age Restriction	Use in infants and toddlers (under 3 years old) is generally advised against unless recommended by a healthcare provider.
Clinical State	Not intended to treat or prevent an eye infection or trauma; consultation is required if these conditions are present.
Product Integrity	Must not purchase or use any product subject to FDA warnings or recalls due to contamination or lack of sterility.

For pregnant and lactating women, many artificial tear formulations are classified as acceptable due to negligible systemic exposure, but patients should confirm with the specific product's labeling.

Use of formulations containing the preservative Benzalkonium chloride (BAK) may be restricted or limited for contact lens wearers, as BAK can be absorbed by the lenses.

Interaction scope

The interaction profile of Artificial Tear preparations containing Hypromellose is highly restricted by its fundamental nature as a pharmacologically inert polymer with negligible systemic absorption. Consequently, government regulatory documents report no clinically significant systemic interactions with orally administered medicines, alcohol, food, or herbal products. No specific systemic medicinal products are explicitly listed as interacting substances in official regulatory labeling.

Interaction classifications (high-level)

This product’s only documented interaction is a local physical phenomenon with other Topical Ophthalmic Medicinal Products (e.g., eye drops and eye ointments). This local effect stems from the solution's viscosity-enhancing properties, which is officially described as a Local Viscoelastic Effect that results in the prolonged ocular contact time for co-administered agents. Due to this physical interaction, official labeling specifies a regulatory constraint classified as an Administration Timing Constraint.

Resulting interaction structure

Official interaction statements confirm that the product is not expected to be a substrate or participant in CYP-mediated or transporter-mediated systemic interactions. This inert profile dictates the only procedural constraint: mandatory administration separation. Regulatory documents mandate a minimum separation interval (typically ge 5 minutes) between applying this solution and any other topical ophthalmic product. This constraint is required to ensure that the subsequent medicinal product is not diluted or washed out, thereby preserving its intended action. Official labeling does not include population-specific interaction considerations.

Artificial tears deliver a viscous layer to the ocular surface, immediately modulating the physical properties of the pre-corneal tear film. The core mechanism involves utilizing viscosity enhancers, such as carboxymethylcellulose (CMC), to elevate the viscosity of the aqueous layer. This action extends the residency time of the solution on the corneal surface by slowing the rate of drainage and evaporation.

Downstream, the sustained hydrogel interface functions to reduce the coefficient of friction between the palpebral conjunctiva and the corneal epithelium during blinking. Additionally, the inclusion of key electrolytes (e.g., potassium and sodium) supports the overall system-level physiological consequence by contributing to the osmotic and ionic balance required for the normal physiological function of the ocular surface epithelium.

Artificial tears, which include drops, gels, and ointments, are used topically to lubricate the eye and temporarily relieve dryness and irritation. For correct application and safety, follow the steps below and consult your product's specific label instructions for frequency of use.

Proper Administration Technique

Step	Instruction
1. Preparation	Wash your hands thoroughly with soap and water before use.
2. Positioning	Tilt your head back or lie down. Use one finger to gently pull your lower eyelid down, creating a small pouch or pocket.
3. Instillation	Hold the dropper tip close to the pouch without allowing it to touch your eye, eyelid, or any other surface to prevent contamination. Squeeze out the prescribed or recommended number of drops (usually one to two).
4. Retention	Gently close your eye for at least one minute. You may press lightly on the inner corner of your eyelid, near your nose, to help keep the drop from draining away. Avoid squeezing your eyes shut or blinking rapidly.

---

Important Considerations

• Preservatives and Frequency: If you need to use artificial tears more than four to six times per day, preservative-free drops are generally recommended, as the preservatives in multi-dose bottles may cause irritation with frequent use.
• Contact Lenses: Check the label of your specific product. Generally, contact lenses should be removed before using non-rewetting drops (especially gels or ointments) and should remain out for at least 10 to 15 minutes after application.
• Other Products: If using more than one type of eye drop, wait at least five minutes between applications to ensure each medication is absorbed properly.

Research evidence / Overview of Studies for Artificial Tear

Evidence for Use in Dry Eye Disease (DED)

Studies have been conducted on artificial tear solutions containing ingredients like Hypromellose for individuals experiencing symptoms of Dry Eye Disease (DED). Research primarily utilized Randomized Controlled Trials (RCTs) and Systematic Reviews, where the tear substitute was evaluated in adult populations diagnosed with mild to moderate DED. These clinical trials were used in research exploring how symptoms change over time and how the solution compares to other tear substitutes or non-medicated solutions like saline.

In these studies, researchers monitored outcomes related to physical discomfort, including patient-reported outcomes describing perceived discomfort such as dryness, burning, and irritation. Studies also explored changes in objective measures of tear film stability, such as Tear Film Break-up Time (TBUT). The findings describe patterns observed in the studies related to changes in these symptoms, particularly in the short term. Systematic reviews note that sample sizes were modest in some of the older trials, and evidence quality varies across studies when comparing Hypromellose to other tear substitutes.

---

Evidence in Contact Lens Wearers

Research was studied for its application in individuals who experience symptoms of dry eye and irritation while wearing contact lenses. These studies have primarily applied in research contexts involving fluctuating or unstable symptoms related to lens wear. This evidence contributes to the broader evidence landscape by detailing the conditions under which the solution was evaluated in these specific wearers.

---

Long-Term Studies and Follow-Up Duration

The typical follow-up durations in clinical research have mostly been short-term (ranging from one to several months). Research has primarily focused on episodes where symptoms become more noticeable, and follow-up durations were limited in many cases. Consequently, long-term effects are not fully established, and there is limited information for long-term outcomes or the persistence of observed changes over intermediate and extended follow-up periods.

---

What Research Remains Uncertain

Research provides context but not individual predictions. The primary remaining uncertainties relate to comparative data, with comparative evidence is lacking for a full description of the differences among common artificial tear formulations. Furthermore, data are still emerging regarding the overall role of artificial tears in the management plan for DED, and few data are available specifically addressing the use in people with severe DED symptoms.

Key Studies & References

1. Artificial tears for dry eye syndrome: a systematic review and meta-analysis of clinical trials
2. TFOS DEWS II Management and Therapy Report

Common questions about Artificial Tear (FAQ)

---

Q: Can artificial tears help with eye redness and irritation?

Official product information states that artificial tears are indicated for the symptomatic relief of eye irritation and dry eye conditions. However, eye redness (ocular hyperaemia) is also listed as a potential, typically transient, side effect of the drops in regulatory documents.

---

Q: How quickly do artificial tears start to relieve the dryness?

Official documentation describes the product's function as providing prompt, physical relief of dry eye symptoms, consistent with its mechanical function as a lubricant. This physical action occurs immediately on instillation, based on the drops acting as a mechanical tear substitute.

---

Q: Is it possible for artificial tears to cause a mild allergic reaction?

Regulatory documents state that a serious systemic allergic reaction is rare. However, the product is contraindicated, meaning its use is officially not recommended for individuals with a known hypersensitivity (allergy) to the product or its components.

---

Q: Can artificial tears be used to relieve eye strain?

Official regulatory documents indicate that these drops can provide relief for dry eye symptoms associated with using Visual Display Units (VDUs) and infrequent blinking. This use is consistent with the product acting as a lubricant for symptoms of dryness caused by these visual activities.

---

Q: Is it normal for the drops to sometimes leak out onto the cheek?

Administration guidelines mention techniques, such as pressing lightly on the inner corner of the eye near the nose, intended to help keep the drop from draining away. The inclusion of this administration step indicates that some drainage or leakage is a known physical possibility during the application process.

---

Q: Can environmental factors like wind or low humidity affect how well artificial tears work?

Official documentation describes the drops' use as helping with discomfort associated with exposure to various environmental factors. This includes conditions such as air conditioning, central heating, wind, and sun.

---

Q: Is it known if certain medical conditions make artificial tears less effective?

Official information confirms that Hypromellose is indicated for dry eye conditions associated with specific medical issues, such as keratoconjunctivitis sicca (dry eye) accompanying rheumatoid arthritis or keratitis. Official product documents do not generally address the efficacy of the drops when used by people with a broader range of non-ocular medical conditions.

---

Q: Do artificial tears have an effect on natural tear production over time?

Official pharmacological properties describe the active substance as pharmacologically inert and not absorbed systemically. Because the substance is pharmacologically inert and not absorbed, it is not expected to interfere with the body's natural physiological processes for producing tears.

Storage and Handling

Artificial Tear products must be stored at room temperature, adhering to the manufacturer's specific guidelines, and must not be frozen. Storage requirements strictly mandate keeping the product away from moisture and ensuring the cap is tightly closed immediately after use. This maintains the product's integrity and sterility. Do not touch the dropper tip to any surface, including the eye, to prevent contamination.

Stability and Child Safety

Use the product only up to the manufacturer's expiration date printed on the label; discard the medicine if it becomes cloudy or changes color. As a safety protocol, keep all medications, including Artificial Tears, out of the reach of children and pets.

Official Disposal Rules

Artificial Tears are generally classified as non-flushable, non-hazardous waste. The preferred method of disposal is through a local drug take-back program or mail-back service. If these options are unavailable, the medication should be mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed container, and then thrown into the household trash.